Ruhé Henricus G, Booij Jan, Reitsma Johannes B, Schene Aart H
Department of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Eur J Nucl Med Mol Imaging. 2009 May;36(5):841-9. doi: 10.1007/s00259-008-1057-x. Epub 2009 Jan 30.
The serotonin system is undoubtedly involved in the pathogenesis of major depressive disorder (MDD). More specifically the serotonin transporter (SERT) serves as a major target for antidepressant drugs. There are conflicting results about SERT availability in depressed patients versus healthy controls. We aimed to measure SERT availability and study the effects of age, gender and season of scanning in MDD patients in comparison to healthy controls.
We included 49 depressed outpatients (mean+/-SD 42.3 +/- 8.3 years) with a Hamilton depression rating scale score above 18, who were drug-naive or drug-free for >or=4 weeks, and 49 healthy controls matched for age (+/-2 years) and sex. Subjects were scanned with single photon emission computed tomography (SPECT) using [(123)I]beta-CIT. SERT availability was expressed as specific to nonspecific binding ratios (BP(ND)) in the midbrain and diencephalon with cerebellar binding as a reference.
In crude comparisons between patients and controls, we found no significant differences in midbrain or diencephalon SERT availability. In subgroup analyses, depressed males had numerically lower midbrain SERT availability than controls, whereas among women SERT availability was not different (significant diagnosis x gender interaction; p = 0.048). In the diencephalon we found a comparable diagnosis x gender interaction (p = 0.002) and an additional smoking x gender (p = 0.036) interaction. In the midbrain the season of scanning showed a significant main effect (p = 0.018) with higher SERT availability in winter.
Differences in SERT availability in the midbrain and diencephalon in MDD patients compared with healthy subjects are affected by gender. The season of scanning is a covariate in the midbrain. The diagnosis x gender and gender x smoking interactions in SERT availability should be considered in future studies of the pathogenesis of MDD.
血清素系统无疑参与了重度抑郁症(MDD)的发病机制。更具体地说,血清素转运体(SERT)是抗抑郁药物的主要靶点。关于抑郁症患者与健康对照者的SERT可用性,存在相互矛盾的结果。我们旨在测量MDD患者的SERT可用性,并研究年龄、性别和扫描季节对其的影响,同时与健康对照者进行比较。
我们纳入了49名抑郁门诊患者(平均±标准差42.3±8.3岁),其汉密尔顿抑郁量表评分高于18分,未服用过药物或停药≥4周,以及49名年龄(±2岁)和性别相匹配的健康对照者。受试者使用[(123)I]β-CIT进行单光子发射计算机断层扫描(SPECT)。SERT可用性以中脑和间脑中特异性与非特异性结合比率(BP(ND))表示,以小脑结合作为参考。
在患者与对照者的粗略比较中,我们发现中脑或间脑的SERT可用性没有显著差异。在亚组分析中,抑郁男性的中脑SERT可用性在数值上低于对照者,而女性之间的SERT可用性没有差异(诊断×性别交互作用显著;p = 0.048)。在间脑中,我们发现了类似的诊断×性别交互作用(p = 0.002)以及额外的吸烟×性别交互作用(p = 0.036)。在中脑中,扫描季节显示出显著的主效应(p = 0.018),冬季的SERT可用性更高。
与健康受试者相比,MDD患者中脑和间脑SERT可用性的差异受性别影响。扫描季节是中脑的一个协变量。在未来MDD发病机制的研究中,应考虑SERT可用性方面的诊断×性别和性别×吸烟交互作用。